[
    [
        {
            "time": "2018-01-27",
            "original_text": "利妥昔首仿将上市，国内生物类似药进度盘点【周观点|长江医药0127】",
            "features": {
                "keywords": [
                    "利妥昔",
                    "首仿",
                    "生物类似药",
                    "进度",
                    "长江医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "利妥昔首仿将上市，国内生物类似药进度盘点【周观点|长江医药0127】",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-27",
            "original_text": "生物仿制药重磅利好！这家公司即将拿到首个批文，还有一批在路上",
            "features": {
                "keywords": [
                    "生物仿制药",
                    "利好",
                    "公司",
                    "首个批文",
                    "复星医药"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "生物仿制药重磅利好！这家公司即将拿到首个批文，还有一批在路上",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-27",
            "original_text": "审批新规首个生物仿制药即将获批，复星医药旗下复宏汉霖抢得头筹",
            "features": {
                "keywords": [
                    "审批新规",
                    "生物仿制药",
                    "复星医药",
                    "复宏汉霖",
                    "头筹"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "审批新规首个生物仿制药即将获批，复星医药旗下复宏汉霖抢得头筹",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-27",
            "original_text": "首个生物仿制药即将获批 复宏汉霖抢得头筹",
            "features": {
                "keywords": [
                    "生物仿制药",
                    "获批",
                    "复宏汉霖",
                    "头筹"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "首个生物仿制药即将获批 复宏汉霖抢得头筹",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-27",
            "original_text": "公募老将选股思路延续 高ROE成为首要标准",
            "features": {
                "keywords": [
                    "公募",
                    "选股思路",
                    "高ROE",
                    "首要标准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "公募老将选股思路延续 高ROE成为首要标准",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-27",
            "original_text": "【中泰一周微视】钢铁/银行/建材/地产/化工/医药/零售/通信/军工",
            "features": {
                "keywords": [
                    "钢铁",
                    "银行",
                    "建材",
                    "地产",
                    "化工",
                    "医药",
                    "零售",
                    "通信",
                    "军工"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "多行业"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【中泰一周微视】钢铁/银行/建材/地产/化工/医药/零售/通信/军工",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]